compound semaglutide going away Compounded semaglutide: What should patients know? FDA restricts non-approved compounded GLP-1

Together, these findings necessitate further investigations to ascertain whether coordinated inhibition of NMDA receptors in GLP-1 receptor neurons modulates neuronal activity beyond canonical feeding regions, such as the mesolimbic dopaminergic reward pathway

Biochem J (2015) 466(1):111.10.1042/BJ20141293 2 BrooksAJDehkhodaFKragelundBB

Validation: Jinguang Wang

From hypoxia and hypoxia-inducible factors (HIF) to oxidative stress: A new understanding of the toxic mechanism of mycotoxins

In the Phase 2 trial published in the New England Journal of Medicine, researchers documented cutaneous hyperesthesia in approximately 7% of retatrutide participants compared to just 1% in the placebo group